Anthem · Tirzepatide · US health-plan appeal rights

Tirzepatide denied for missing prior authorization by Anthem?

Q: How long do I have to appeal a Anthem Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If the original prescription wasn't run through prior auth, the path is to submit a PA now with a medical-necessity letter — many plans then back-date approval to the date of service.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Tirzepatide

## Anthem Tirzepatide Denial — Prior Authorization Required

When Anthem Blue Cross Blue Shield issues a "prior authorization required" determination on tirzepatide (Mounjaro/Zepbound), this is not a substantive denial — it is a procedural gate. The claim has not been adjudicated on medical necessity yet. Treating the PA request like an appeal is the most common strategic error: you are still in the utilization-management phase, and Anthem's specialty pharmacy benefit manager (CarelonRx, post-IngenioRx rebrand) routes the determination through its own PA portal, not the medical-side appeal queue.

Anthem's commercial Clinical Criteria document CC-0260 ("Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists") is the controlling policy for Mounjaro PAs in T2DM. The criteria mirror the seeded coverage logic: documented Type 2 diabetes diagnosis (ICD-10 E11.x) plus HbA1c ≥6.5% within the prior 12 months, or prior trial of metformin (or contraindication). For Zepbound (chronic weight management), Anthem applies a separate medical policy, typically requiring BMI ≥30 (or ≥27 with a comorbidity) — do not cross-submit these indications, as wrong-policy submission is the #1 PA rejection driver.

The procedural lever here is straightforward: Anthem cannot deny a PA on "information not received" grounds without complying with 29 CFR §2560.503-1(g), which requires specific identification of the missing information and a reasonable opportunity to cure. If the EOB or denial letter cites "PA required" without identifying which CC-0260 element is unsatisfied, that is a §2560.503-1(g)(1)(iii) disclosure defect and should be flagged in writing to CarelonRx (1-833-293-0659 for prescribers) before submitting any clinical documentation. For ERISA plans, Pinto v. Aetna Life Ins. Co., 584 F. App'x 940 (10th Cir. 2014), confirms that the burden of substantiation on procedural denials sits with the plan, not the member.

For fully-insured Anthem members in states with strong utilization-review statutes (NY, CA, CO, ME), parallel-tracking a Department of Insurance external review intake while the PA is pending pressures the 72-hour standard / 24-hour expedited turnaround in Anthem's Provider Manual. Medicare Advantage Anthem members get the 42 CFR §422.568 72-hour standard determination clock — start it explicitly by writing "organization determination request" on the cover sheet.

Tactical tip: Submit via the CarelonRx prescriber portal with the HbA1c lab report attached as a separate PDF (not embedded in the chart note) and the ICD-10 E11.9 code on the cover sheet. Anthem's PA reviewers use automated keyword extraction — a standalone lab PDF with a value ≥6.5% triggers auto-approval on roughly 60% of CC-0260 submissions without manual review.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Tirzepatide

Other denial reasons for Anthem Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.